Home > Oncology > GnRHa therapy protects the ovaries of young women with breast cancer having chemo

GnRHa therapy protects the ovaries of young women with breast cancer having chemo

Journal
JAMA Oncology
Reuters Health - 03/01/2022 - Treatment with a gonadotropin-releasing hormone analog (GnRHa) during chemotherapy in premenopausal women with breast cancer reduces ovarian impairment, according to a randomized controlled trial conducted in China. Studies on the use of GnRHa therapy to protect ovarian function have shown "mixed results" for a variety of reasons, Dr. Xiangyun Zong of Shanghai Jiao Tong University Affiliated Shanghai Sixth People's Hospital and colleagues note in JAMA Oncology. To investigate, they did an open-label trial involving 330 women aged 18 to 49 years with operable breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned. Half underwent chemotherapy without and half with GnRHa therapy, which consisted of 3.6 mg of goserelin or 3.75 mg of leuprorelin by subcutaneous injection once every 28 days from one to two weeks before the first cycle of chemotherapy to four weeks after the l...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on